Table S2.
Acceptance of submissions with ICERs higher than the threshold by disease area
| NICE n (%) |
SMC n (%) |
CADTH n (%) |
PBAC n (%) |
Pooled results n (%) | |
|---|---|---|---|---|---|
| Total | 22/41 (54) | 18/70 (26) | 7/27 (26) | 16/83 (19) | 64/223 (29) |
| 1. Gastrointestinal system | – | 1/4 (25) | 0/1 (0) | 0/1 (0) | 1/6 (17) |
| 2. Cardiovascular system | – | – | – | 0/1 (0) | 0/1 (0) |
| 3. Respiratory system | 1/1 (100) | 0/1 (0) | – | 0/3 (0) | 1/5 (20) |
| 4. Central nervous system | – | 0/2 (0) | 2/3 (67) | 0/2 (0) | 2/7 (29) |
| 5. Infections | – | 1/5 (20) | 1/5 (20) | 1/4 (25) | 3/14 (21) |
| 6. Endocrine system | – | 2/3 (67) | 0/3 (0) | 1/5 (20) | 3/11 (27) |
| 7. Obstetrics, gynecology, and urinary tract disorders | – | – | – | 1/3 (33) | 1/3 (33) |
| 8. Malignant disease and immunosuppression | 14/32 (44) | 10/45 (22) | 2/6 (33) | 11/47 (23) | 37/131 (28) |
| 9. Nutrition and blood | 0/1 (0) | 2/5 (40) | 1/3 (33) | 0/5 (0) | 3/14 (21) |
| 10. Musculoskeletal and joint diseases | 4/4 (100) | 1/3 (33) | 1/4 (25) | 0/3 (0) | 6/16 (38) |
| 11. Eye | 1/1 (100) | 0/1 (0) | 0/2 (0) | 1/2 (50) | 2/6 (33) |
| 12. Ear, nose, and oropharynx | – | – | – | – | – |
| 13. Skin | 2/2 (100) | 1/1 (100) | – | 1/5 (20) | 4/8 (50) |
| 14. Immunological products and vaccines | – | – | – | – | – |
| 15. Anesthesia | – | – | – | – | – |
Notes: That acceptance here includes restricted submissions; – indicates not applicable.
Abbreviations: ICERs, incremental cost-effectiveness ratios; NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium; CADTH, Canadian Agency for Drugs and Technologies in Health; PBAC, Pharmaceutical Benefits Advisory Committee.